{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T16:07:04Z","timestamp":1779379624620,"version":"3.53.1"},"reference-count":40,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacy"],"abstract":"<jats:p>Background: Tildrakizumab, an anti-IL-23p19 monoclonal antibody, has demonstrated efficacy in clinical trials, but real-world evidence remains crucial for confirming its profile in diverse populations. Methods: We have conducted a multicenter, retrospective observational study within the Spanish Psoriasis Group (GPS). This study updates previous findings with a larger sample size (n = 372) and longer follow-up. We assessed absolute Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), and the Dermatology Life Quality Index (DLQI) improvements, as well as safety, in patients with moderate-to-severe plaque psoriasis. Results: The cohort included a large population of patients with a high prevalence of comorbidities and prior biologic exposure. Effectiveness was high, with a significant proportion of patients achieving PASI &lt; 1. Compared to recent real-world data, our cohort demonstrates superior complete clearance rates (PASI &lt; 1) and includes a comprehensive DLQI assessment. Notably, 79 patients were aged \u226565 years, confirming the drug\u2019s utility in the elderly. Safety was consistent with previous reports, with no new signals detected. Conclusions: Tildrakizumab shows robust effectiveness and safety in a complex, bio-experienced real-world population. The lack of clinical predictors of response suggests a need for future pharmacogenetic exploration.<\/jats:p>","DOI":"10.3390\/pharmacy14030063","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T11:40:12Z","timestamp":1777981212000},"page":"63","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Effectiveness and Safety of Tildrakizumab in a Large Spanish Multicenter Cohort from Spanish Psoriasis Group (GPS)"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1187-1341","authenticated-orcid":false,"given":"Mar","family":"Llamas-Velasco","sequence":"first","affiliation":[{"name":"Department of Dermatology, Hospital Universitario de la Princesa, Instituto de Investigaci\u00f3n Biom\u00e9dica de la Princesa, Universidad Aut\u00f3noma de Madrid, 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2028-638X","authenticated-orcid":false,"given":"Mercedes","family":"Hospital","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario Puerta de Hierro, 28222 Majadahonda, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"L\u00f3pez-Ferrer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Herranz","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario La Paz, 28046 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0381-6174","authenticated-orcid":false,"given":"Ricardo","family":"Ru\u00edz-Villaverde","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario San Cecilio, Instituto Biosanitario de Granada (IBS.GRANADA), 18016 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almudena","family":"Mateu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Garc\u00eda-Latasa","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario Royo Villanova, 50015 Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4604-0724","authenticated-orcid":false,"given":"Raquel","family":"Rivera","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes Rodriguez","family":"Fern\u00e1ndez-Freire","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Virgen del Roc\u00edo, 41013 Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena Del","family":"Alcazar","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Santos","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Virgen de los Lirios, 03804 Alcoy, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4186-1435","authenticated-orcid":false,"given":"Salvador","family":"Arias","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Virgen de las Nieves Hospital, 18014 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"G\u00f3nzalez-Cantero","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario Ram\u00f3n y Cajal, Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitarian (IRYCIS), 28034 Madrid, Spain"},{"name":"Faculty of Medicine, Universidad Francisco de Vitoria Madrid, 28223 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6007-7320","authenticated-orcid":false,"given":"Isabel","family":"Belinchon","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital General Universitario Dr. Balmis, Departamento de Medicina Cl\u00ednica, Instituto de Investigaci\u00f3n Sanitaria y Biom\u00e9dica de Alicante (ISABIAL), Universidad Miguel Hern\u00e1ndez, 03010 Alicante, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregorio","family":"Carretero","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario de Gran Canaria Dr. Negr\u00edn, 35010 Las Palmas de Gran Canaria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Ferran","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital del Mar, 08003 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Ruiz-Genao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario Fundaci\u00f3n Alcorcon, 28922 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noem\u00ed","family":"Eiris","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario Virgen Macarena, 41009 Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Sahuquillo","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitari Doctor Peset, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5749-1160","authenticated-orcid":false,"given":"Javier","family":"Mataix","sequence":"additional","affiliation":[{"name":"Hospital Marina Baixa, 03570 Alicante, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose-Mar\u00eda","family":"Carrascosa","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4807-3551","authenticated-orcid":false,"given":"Pablo de la","family":"Cueva","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Infanta Leonor, 28031 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Salgado-Boquete","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Complejo Hospitalario Universitario de Pontevedra, 36071 Pontevedra, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: Systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"ref_2","unstructured":"Falco, G.M., Ippoliti, E., Gori, N., Caldarola, G., De Simone, C., Di Giorgi, N., Longo, P.G., Galluzzo, M., Bianchi, L., and Marcelli, L. (Int. J. Dermatol., 2026). Superior Clinical and Economic Value of IL-23 Inhibitors Versus Adalimumab Biosimilars in Plaque Psoriasis, Int. J. Dermatol., in press."},{"key":"ref_3","first-page":"1106","article-title":"Optimizing biologics for chronic plaque psoriasis: Insights on non-medical interruptions of IL-17, IL-12\/23, and IL-23 inhibitors","volume":"23","author":"Huang","year":"2025","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Ahmadipanah, S., Shariat Rad, P., Montaseri, M., Nemati, H., Sadeghi, M., and Ramezani, M. (2026). IL-23 serum levels and IL23R polymorphisms in psoriasis: A meta-analysis of susceptibility and severity. BMC Immunol., 27.","DOI":"10.1186\/s12865-026-00814-y"},{"key":"ref_5","unstructured":"Bulut, S.K., Dursun, R., Findik, S., Temiz, S.A., Uyar, M., Daye, M., Ozer, I., and Caliskan, H. (J. Cutan. Pathol., 2026). IL-17, IL-23, and IL-36alpha Expression in Palmoplantar Psoriasis, Palmoplantar Eczema, and Plaque Psoriasis: Implications on Diagnosis and Treatment Selection, J. Cutan. Pathol., in press."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"540848","DOI":"10.2147\/JIR.S540848","article-title":"IL-23 Inhibitors in Psoriasis: What Have We Learnt so Far?","volume":"19","author":"Megna","year":"2026","journal-title":"J. Inflamm. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): Results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/bjd.18232","article-title":"Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: Pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks","volume":"182","author":"Reich","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1001\/jamadermatol.2018.0183","article-title":"Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR","volume":"154","author":"Mason","year":"2018","journal-title":"JAMA Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1111\/jdv.19468","article-title":"Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group","volume":"37","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s13555-025-01607-8","article-title":"Real-World Effectiveness and Safety of Tildrakizumab in Moderate-to-Severe Psoriasis: A Multicenter Experience in the Basque Country","volume":"16","year":"2026","journal-title":"Dermatol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2598183","DOI":"10.1080\/09546634.2025.2598183","article-title":"Tildrakizumab in real-world Chinese psoriasis: Efficacy-safety profiles from a 28-week retrospective cohort with geriatric, late-onset and metabolic syndrome stratification","volume":"36","author":"Liu","year":"2025","journal-title":"J. Dermatol. Treat."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1111\/jdv.19229","article-title":"Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-to-severe plaque psoriasis patients in conditions close to clinical practice","volume":"37","author":"Costanzo","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"754","DOI":"10.36849\/jdd.7471","article-title":"Real-World Effectiveness and Safety of Tildrakizumab in Patients With Moderate-to-Severe Psoriasis: Week 28 Interim Analysis of a Phase 4 Study","volume":"22","author":"Heim","year":"2023","journal-title":"J. Drugs Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/jdv.18572","article-title":"Real-world effectiveness and safety of tildrakizumab in long-term treatment of plaque psoriasis: Results from the non-interventional, prospective, multicentre study TILOT","volume":"37","author":"Tsianakas","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1159\/000519924","article-title":"Effective and Safe Treatment of Psoriatic Disease with the Anti-IL-23p19 Biologic Tildrakizumab: Results of a Real-World Prospective Cohort Study in Nonselected Patients","volume":"238","author":"Drerup","year":"2022","journal-title":"Dermatology"},{"key":"ref_17","first-page":"e15488","article-title":"Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study","volume":"35","author":"Caldarola","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_18","first-page":"e355","article-title":"Tildrakizumab: Short-term efficacy and safety in real clinical practice","volume":"61","year":"2022","journal-title":"Int. J. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ruiz-Villaverde, R., Rodriguez Fernandez-Freire, L., Font-Ugalde, P., and Galan-Gutierrez, M. (2022). Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks) in Three Tertiary Hospitals in Andalucia (Spain). J. Clin. Med., 11.","DOI":"10.3390\/jcm11175098"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/jdv.18594","article-title":"Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis)","volume":"37","author":"Narcisi","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2147\/PTT.S525256","article-title":"Effectiveness and Safety of Tildrakizumab in Elderly and Frail Elderly Psoriatic Patients Up to 2 years","volume":"15","author":"Mastorino","year":"2025","journal-title":"Psoriasis"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2147\/CCID.S402183","article-title":"Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study","volume":"16","author":"Ruggiero","year":"2023","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_23","first-page":"2021-2-6","article-title":"Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting","volume":"10","author":"Burlando","year":"2021","journal-title":"Drugs Context"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"612","DOI":"10.36849\/JDD.8217","article-title":"Tildrakizumab Real-World Effectiveness and Safety Over 64 Weeks in Patients With Moderate-to-Severe Plaque Psoriasis","volume":"23","author":"Heim","year":"2024","journal-title":"J. Drugs Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/ced\/llae433","article-title":"Impact of tildrakizumab on the quality of life of patients with moderate-to-severe psoriasis: A 36-week prospective monocentric real-life observational study","volume":"50","author":"Cacciapuoti","year":"2025","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/jdv.15400","article-title":"Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: Pooled analysis of three randomized controlled trials at weeks 12 and 28","volume":"33","author":"Papp","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/bjd.19866","article-title":"Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: Pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)","volume":"185","author":"Thaci","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jaad.2019.09.042","article-title":"Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)","volume":"82","author":"Lebwohl","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_29","first-page":"6772","article-title":"Psoriasis patients\u2019 characteristics associated with high PASI response to tildrakizumab: An international dual center study","volume":"26","author":"Burlando","year":"2022","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1111\/jdv.15862","article-title":"Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: A pooled analysis of two randomized controlled trials","volume":"33","author":"Blauvelt","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2310631","DOI":"10.1080\/09546634.2024.2310631","article-title":"Long-term quality of life outcomes from a phase 4 study of tildrakizumab in patients with moderate-to-severe plaque psoriasis in a real-world setting","volume":"35","author":"Bhatia","year":"2024","journal-title":"J. Dermatol. Treat."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Tsianakas, A., Magnolo, N., Kempf, A., Andersohn, F., Kirsch, A., Kokolakis, G., and Niebel, D. (2026). Tildrakizumab Real-World Experience (T-REX) in Plaque Psoriasis: Meta-Analysis of Four Non-interventional Studies. Dermatol. Ther.","DOI":"10.1007\/s13555-026-01713-1"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s13555-025-01625-6","article-title":"Real-World Benefit of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: Findings from a Systematic Literature Review and Meta-Analysis","volume":"16","author":"Gottlieb","year":"2026","journal-title":"Dermatol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1007\/s13555-025-01529-5","article-title":"Biologic Therapies and Major Cardiovascular Events in Psoriasis: Updated Systematic Review and Meta-analysis","volume":"15","author":"Mangkorntongsakul","year":"2025","journal-title":"Dermatol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1080\/14740338.2022.2160447","article-title":"Drug safety evaluation of tildrakizumab for psoriasis: A review of the current knowledge","volume":"21","author":"Ruggiero","year":"2022","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"703","DOI":"10.36849\/JDD.2020.5337","article-title":"The Effect of Tildrakizumab on Cardiometabolic Risk Factors in Psoriasis by Metabolic Syndrome Status: Post Hoc Analysis of Two Phase 3 Trials (ReSURFACE 1 and ReSURFACE 2)","volume":"19","author":"Menter","year":"2020","journal-title":"J. Drugs Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1007\/s13555-026-01708-y","article-title":"Efficacy and Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis with Diabetes: Pooled Subgroup Analysis of reSURFACE 1 and reSURFACE 2","volume":"16","author":"Bagel","year":"2026","journal-title":"Dermatol. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/bjd\/ljaf392","article-title":"Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis over 5 years in patients living with obesity","volume":"194","author":"Lebwohl","year":"2026","journal-title":"Br. J. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e15152","DOI":"10.1111\/exd.15152","article-title":"Genetic polymorphisms to identify patients with an optimal response to tildrakizumab in psoriasis patients from real-life clinical practice","volume":"33","author":"Roustan","year":"2024","journal-title":"Exp. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1007\/s13555-025-01538-4","article-title":"Optimizing Psoriasis Treatment with Tildrakizumab: Current Evidence and Expert Recommendations for Treatment Individualization in Clinical Practice","volume":"15","author":"Mateu","year":"2025","journal-title":"Dermatol. Ther."}],"container-title":["Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2226-4787\/14\/3\/63\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:32:58Z","timestamp":1779377578000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2226-4787\/14\/3\/63"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["pharmacy14030063"],"URL":"https:\/\/doi.org\/10.3390\/pharmacy14030063","relation":{},"ISSN":["2226-4787"],"issn-type":[{"value":"2226-4787","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]}}}